SCHEMBL209490

SCHEMBL209490

O=C(c1ccc(-c2cc(Cl)c(CC3CCN(C4CCOCC4)C3=O)c(Cl)c2)cc1)N1CCC(F)(F)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.37
POLB P06746 1/20 0.37
ERN1 O75460 1/20 0.37
MAPK1 P28482 1/20 0.37
HRH3 Q9Y5N1 7/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PKM P14618 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2C P18825 1/20 0.35
CHRM3 P20309 1/20 0.35
DRD4 P21917 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
SLC6A4 P31645 1/20 0.35
HRH1 P35367 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
PHGDH O43175 1/20 0.35
FASN P49327 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209489 1.00 MET (0.37) METPOLBERN1MAPK1HRH3
SCHEMBL3124899 0.93 ERN1 (0.41) METPOLBERN1HRH3NPSR1
SCHEMBL3124891 0.93 ERN1 (0.41) METPOLBERN1HRH3NPSR1
SCHEMBL3130188 0.93 FASN (0.37) METHRH3FASNPDE5APDE4A
SCHEMBL3130194 0.93 FASN (0.37) METHRH3FASNPDE5APDE4A
SCHEMBL2721749 0.91 HSD11B1 (0.41) METHRH3FASNPDE5APDE4A
SCHEMBL209661 0.91 PKM (0.44) METERN1HRH3NPSR1PKM
SCHEMBL209660 0.91 PKM (0.44) METERN1HRH3NPSR1PKM
SCHEMBL208211 0.90 FASN (0.35) METHRH3FASNPDE5APDE4A
SCHEMBL211165 0.90 FASN (0.35) METHRH3FASNPDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 MET 2704/4885POLB 3372/4885ERN1 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.